PAVmed (PAVM) Stock Price, News & Analysis

Company Overview

PAVmed Inc. is a medical device and diagnostics company focused on developing and commercializing technologies intended to improve the diagnosis and treatment of serious medical conditions. The company operates through subsidiaries and strategic business units that address areas including cancer detection, remote patient monitoring, vascular access and minimally invasive procedures.

One of PAVmed’s primary businesses is its majority-owned subsidiary Lucid Diagnostics, which developed the EsoGuard DNA test and EsoCheck cell-collection device. The technologies are designed to help identify patients at elevated risk of esophageal precancer, including Barrett’s esophagus, and are marketed for use in the United States. PAVmed has also pursued products such as the PortIO implantable vascular access device and the CarpX minimally invasive carpal tunnel release system.

Through Veris Health, PAVmed has also developed a remote monitoring platform intended to support cancer care by collecting and transmitting patient health information to care teams. The company was founded in 2014 and is led by Lishan Aklog, M.D., who serves as chairman and chief executive officer. Its operations and commercial activities are primarily focused on the U.S. healthcare market.

Key Stats

• Today's Range: $2.39 to $2.50
• 50-Day Range: $2.29 to $5.35
• 52-Week Range: $2.22 to $28.44
• Volume: 12,563 shs
• Average Volume: 21,871 shs
• Market Capitalization: $19.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.00
• Consensus Rating: Hold

PAVmed Stock Analysis - MarketRank™

PAVmed scored higher than 54% of companies evaluated by MarketBeat, and ranked 494th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

PAVmed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

PAVmed has a consensus price target of $56.00, representing about 2,223.7% upside from its current price of $2.41.

Amount of Analyst Coverage

PAVmed has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PAVmed are expected to grow in the coming year, from ($2.74) to ($2.55) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.18% of the float of PAVmed has been sold short.

Short Interest Ratio / Days to Cover

PAVmed has a short interest ratio ("days to cover") of 0.76, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PAVmed has recently increased by 16.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PAVmed does not currently pay a dividend.

Dividend Growth

PAVmed does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: N/A

News Sentiment

PAVmed has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

Search Interest

1 people have searched for PAVM on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added PAVmed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PAVmed insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.40% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

19.93% of the stock of PAVmed is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:PAVM
• CIK: 1624326
• Web: www.pavmed.com
• Phone: (212) 949-4319
• Fax: N/A
• Employees: 41
• Year Founded: 2014

Price Target and Rating

• Average Price Target for PAVmed: $56.00
• High Price Target: $56.00
• Low Price Target: $56.00
• Potential Upside/Downside: +2,223.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($16.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $400 thousand
• Net Margins: -10,794.64%
• Pretax Margin: -14,669.64%
• Return on Equity: -126.43%
• Return on Assets: -25.49%

Debt

• Debt-to-Equity Ratio: 0.98
• Current Ratio: 1.19
• Quick Ratio: 1.19

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 275.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.42) per share
• Price / Book: -1.00

Miscellaneous

• Outstanding Shares: 8,000,000
• Free Float: 6,925,000
• Market Cap: $19.28 million
• Optionable: No Data
• Beta: 0.69